Former deputy Treasury Secretary Roger Altman said he did not think Jerome Powell would agree to leave if the president asked ...

Stocks rebounded on Wednesday after President Donald Trump denied reports that he was close to ousting Powell as chairman of ...

Wolfe Research reaffirmed its ‘Outperform’ rating on UnitedHealth Group but cut its price target to $330 from $363, citing ongoing medical billing pressures. The firm highlighted that UnitedHealth’s ...

Fintel reports that on July 14, 2025, Wolfe Research downgraded their outlook for HF Sinclair (NYSE:DINO) from Peer Perform ...

Tepfer, published in the Cambridge Archaeological Journal, explores the transformation of elk rock art in the Mongolian Altai ...

Centene Corporation (NYSE:CNC) is one of the 10 Best Growth Stocks to Buy With Huge Upside Potential. On July 2, Wolfe ...

Shares of MongoDB (MDB) rose about 2% on Wednesday after Wolfe Research began coverage on the database software company with ...

Fintel reports that on July 9, 2025, Wolfe Research upgraded their outlook for Fox (NasdaqGS:FOXA) from Underperform to Peer ...

Overall, Wolfe favors a mix of growth and value as the second half of 2025 begins. Related articles Wolfe Research refreshes high-conviction ideas heading into H2 ...

Wolfe Research’s analysts highlighted that the company could see $1.8 billion in tax savings in 2025 alone. This is a 30% free cash flow (FCF) boost, potentially doubling FCF per share by 2027.

The research firm reiterated the company’s solid position amid the “TTR craze” while also echoing its commercial execution strategy. Wolfe Research Initiates Coverage of BridgeBio Pharma ...